Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


Biosimilars and Biobetters USA

07 Apr 2014 - 08 Apr 2014 - Iselin, NJ, USA



Bookmark and Share


Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, this meeting will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Read more:

After the phenomenal success of our Biosimilars and Biobetters event hosted in London in October, the SMi Group is delighted to announce the launch of the Biosimilars & Biobetters Conference in Iselin, New Jersey, USA, in April 2014. Registration is now open.

Through a series of exciting panel discussions, presentations and workshops, delivered by true industry experts and players, the Biosimilars and Biobetters USA conference will offer effective strategies and solutions for developing cost effective biosimilars for the future.

Event’s website: www.smi-online.co.uk/2014biosimilars_usa20.asp 

Benefits of attending:

-      Gain up to date insight into the regulatory landscape and how it is effecting the industry

-      Evaluate commercialization and development strategies to gain a competitive advantage 

-      Calculate possible revenue streams from biosimilar production

-      Discover what lessons have been learned so far and what the future holds 

-      Boost your industry knowledge and relationships by networking and learning from key industry and academic leaders

Key speakers include:

-      Dr Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

-      Dr John Pakulski, Senior Director, and Head US Biopharmaceutical Regulatory Affairs, Sandoz

-      Rodeina Challand, Executive Director, Biosimilars Development, Scientific Affairs, PRA International

-      Dr Stanley (SeungSuh) Hong, President, Research and Development, Celltrion Inc.

-      Paul Ashton, President & CEO, pSivida

-      Peter Pitts, President, Center for Medicine in the Public Interest (Former FDA Associate Commissioner)

-      Douglas M. Long, Vice President, Industry Relations, IMS Health

-      Dr Rakesh Dixit, Vice President, Research and Development Head, Global Biologics Safety Assessment, MedImmune (AstraZeneca Biologics), and many others. 

Don’t miss a chance to visit 2 interactive post-conference workshops:

A.    Differentiation Strategies for the Generics Industry. Workshop Leader: Asa Cox, Founder & CEO, Generic Pharma 2.0

B.    Launching a Biosimilar in an Innovator v. Generic World. Workshop Leader: Kristie Kuhl, JD, Executive VP, Makovsky

For further information please contact Jonathan Collins on +44 (0)20 7827 6734 or email: pharma@smiconferences.co.uk  



Further information
Scientific News
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!